Katherine Chastain

Suppressing STAT5 signaling affects osteosarcoma growth and stemness

Dharmalingam Subramaniam, Pablo Angulo, Sivapriya Ponnurangam et al. · Cell Death and Disease · 2020 · 94 citations · Full text

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z. Usmani, Thierry Façon, Vânia Hungria et al. · Nature Medicine · 2025 · 74 citations · Full text

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study

Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos et al. · Cancer · 2023 · 67 citations · Full text

Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).

Niels W.C.J. van de Donk, Philippe Moreau, Alfred L. Garfall et al. · Journal of Clinical Oncology · 2023 · 60 citations

Immunology, Immunoediting, Immunotherapeutics +21

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation

Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos et al. · Blood Advances · 2023 · 60 citations · Full text

Humoral Response, Immunology, Immunoediting +16